Chronotherapy targeting cytokine secretion attenuates collagen-induced arthritis in mice

Int Immunopharmacol. 2020 Jul:84:106549. doi: 10.1016/j.intimp.2020.106549. Epub 2020 May 18.

Abstract

Objective: Diurnal variation of symptoms are observed in rheumatoid arthritis, especially in productions of cytokines that show peak concentrations during mid night. In contrast, cytokines of collagen-induced arthritis (CIA) mice increase in daytimes under Mid-light condition. By using chronotherapy, differences in drug efficacies according to administration time of Baricitinib, a wide ranged cytokine blocker, were examined in CIA mice.

Methods: CIA mice were administered a dose of 3 mg/kg of Baricitinib once a day at zeitgeber time (ZT) 0 or ZT12 for 21 days. Arthritis scores, histopathology and factors related to joint destruction in sera were examined. Phosphorylation of STAT3 in liver, expressions of cytokines in spleen, and Interleukin (IL)-6 and tumor necrosis factor (TNF)-α in sera were measured.

Results: In CIA mice, diurnal variations were observed both in expressions of cytokines and phosphorylation of STAT3. Arthritis scores of ZT0/12 group decreased from day3 as compared to untreated mice, and those of ZT0 group significantly decreased as compared to ZT12 group from day12. Pathological findings, immunohistochemistry of cytokines and Receptor activator of nuclear factor kappa-Β ligand (RANKL)/osteoprotegerin ratio in sera well reflected results of arthritis scores. Diurnal variation of STAT3 phosphorylation was suppressed in ZT0 group. At ZT2, expressions of IL-6/Interferon-γ/TNF/granulocyte-macrophage colony-stimulating factor in ZT0 group were significantly decreased as compared to untreated mice, though not in ZT12 group. In ZT0 group, IL-6 and TNF-α in sera were decreased for longer time than that in ZT12 group.

Conclusion: Chronotherapy using Baricitinib targeting cytokine secretions is effective in CIA mice. Clinical applications of chronotherapy can be expected to enhance the drug efficacy.

MeSH terms

  • Animals
  • Arthritis, Experimental / drug therapy*
  • Arthritis, Experimental / genetics
  • Arthritis, Experimental / immunology
  • Arthritis, Rheumatoid / drug therapy*
  • Arthritis, Rheumatoid / genetics
  • Arthritis, Rheumatoid / immunology
  • Azetidines / administration & dosage*
  • CLOCK Proteins / genetics
  • Cytokines / immunology*
  • Drug Chronotherapy*
  • Female
  • Lymphocytes / drug effects
  • Lymphocytes / immunology
  • Mice, Inbred DBA
  • Purines / administration & dosage*
  • Pyrazoles / administration & dosage*
  • Spleen / cytology
  • Sulfonamides / administration & dosage*

Substances

  • Azetidines
  • Cytokines
  • Purines
  • Pyrazoles
  • Sulfonamides
  • CLOCK Proteins
  • baricitinib